Proc Natl Acad Sci 79(2):345349 Ma Y, Huang Y, Yan L, Gao M, Liu D (2013) Synthetic FXR agonist GW4064 prevents diet-induced hepatic steatosis and insulin resistance
Its active ingredient, semaglutide, mimics a gut hormone called GLP-1, which delays gastric emptying and signals to the brain that you are full
Tirzepatide Dual-action drug, targeting both glucose metabolism and appetite regulation
Contact list: Have your doctors phone number and the manufacturers helpline number readily available
Results showed that GLP-1 receptor agonists and SGLT2 inhibitors were superior in reducing the risk of MACE when compared to DPP-4 inhibitors (HR 086 [082089] and 086 [082090], respectively), but no difference was found between SGLT2 inhibitors and GLP-1 receptor agonists in reducing rate of MACE (HR of 101 (094107)) ( Conclusion In conclusion, CVOTs have played a pivotal role in evaluating the cardiovascular safety and efficacy of GLP-1 receptor agonists in patients with T2D
Do not expect to see results overnight